SRR1092706
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.374
- TNFA_SIGNALING_VIA_NFKB+0.289
- CHOLESTEROL_HOMEOSTASIS+0.280
- INTERFERON_GAMMA_RESPONSE+0.263
- BILE_ACID_METABOLISM+0.251
- TGF_BETA_SIGNALING+0.246
- IL6_JAK_STAT3_SIGNALING+0.239
- IL2_STAT5_SIGNALING+0.226
- INFLAMMATORY_RESPONSE+0.219
- COAGULATION+0.195
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.491
- HEDGEHOG_SIGNALING-0.436
- MYC_TARGETS_V2-0.259
- G2M_CHECKPOINT-0.226
- E2F_TARGETS-0.202
- KRAS_SIGNALING_DN-0.181
- OXIDATIVE_PHOSPHORYLATION-0.158
- APICAL_SURFACE-0.153
- PI3K_AKT_MTOR_SIGNALING-0.149
- UNFOLDED_PROTEIN_RESPONSE-0.146
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1333694 | GTEX | — | 0.860 |
| 2 | SRR1486304 | GTEX | — | 0.856 |
| 3 | SRR1429244 | GTEX | — | 0.851 |
| 4 | SRR599486 | GTEX | — | 0.849 |
| 5 | SRR1402840 | GTEX | — | 0.824 |
| 6 | SRR1488172 | GTEX | — | 0.823 |
| 7 | SRR1413768 | GTEX | — | 0.816 |
| 8 | SRR1073755 | GTEX | — | 0.809 |
| 9 | SRR612311 | GTEX | — | 0.803 |
| 10 | SRR1085782 | GTEX | — | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.374 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.289 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.263 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.251 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.246 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.239 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.226 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.219 | Idelalisib | — uncovered |
| COAGULATION | 0.195 | Binimetinib | — uncovered |
| APOPTOSIS | 0.189 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.169 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.146 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.139 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.123 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.109 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.106 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| COMPLEMENT | 0.082 | Inavolisib | — uncovered |